The challenges and trends of cell & gene therapies
Drug Discovery World
SEPTEMBER 6, 2022
This will be driven in a major way through breadth of ongoing research and an increased move to better tolerated, logistically simpler allogeneic platforms, such as the optimized Natural Killer (NK) cell therapies being developed at ONK Therapeutics. Chris Nowers, CEO, ONK Therapeutics. . “ Víctor Cervera-Carrascón, Tilt Bio. .
Let's personalize your content